Application of preparation of kit for quality control and curative effect prediction of CAR-T (Chimeric Antigen Receptor-T) cells

By preparing kits for CAR-T cell quality control and efficacy prediction, using tyrosine phosphorylated proteome analysis, the shortcomings of the prior art in evaluating and predicting the efficacy of CAR-T cell therapy are solved, and more accurate and sensitive efficacy prediction is achieved.

CN119738572AActive Publication Date: 2025-04-01SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
2 Cites 0 Cited by

Patent Information

Application Number
CN202411688022.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-22
Publication Date
2025-04-01
Estimated Expiration
2044-11-22

AI Technical Summary

Technical Problem

The prior art has shortcomings in evaluating and predicting the clinical therapeutic effects of CAR-T cell therapy, especially in the comprehensive evaluation of the biological properties of CAR-T cells.

Method used

The efficacy of CAR-T cells is predicted by preparing a kit for the preparation of CAR-T cell quality control and efficacy prediction, including protein acquisition, enzymatic lysis, enrichment of tyrosine phosphorylated proteins, principal component analysis and identification of tyrosine phosphorylation sites.

Benefits of technology

A more accurate and sensitive method is provided to predict the quality control and efficacy of CAR-T cells. By analyzing the differences in tyrosine phosphorylated proteomes, the effectiveness of CAR-T cell therapy can be more accurately evaluated.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of bioinformatics, particularly relates to application of a kit for preparing CAR-T cell quality control and curative effect prediction, and more particularly relates to application of the kit for preparing the CAR-T cell quality control and curative effect prediction, and a panel for curative effect prediction of CAR-T cell therapy. According to the method disclosed by the invention, the tyrosine phosphorylated proteome is creatively used as a core for predicting the quality control and the curative effect of the CAR-T cells, and a more accurate and sensitive method for predicting the quality control and the curative effect of the CAR-T cells is provided.
Need to check novelty before this filing date? Find Prior Art